AJP - GI Journal of Neurophysiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Gastrointest Liver Physiol 292: G512-G517, 2007. First published October 5, 2006; doi:10.1152/ajpgi.00227.2006
0193-1857/07 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
292/2/G512    most recent
00227.2006v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Reid, K. M.
Right arrow Articles by Geller, D. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Reid, K. M.
Right arrow Articles by Geller, D. A.

LIVER AND BILIARY TRACT

Liver I/R injury is improved by the arginase inhibitor, N{omega}-hydroxy-nor-L-arginine (nor-NOHA)

Kaye M. Reid,1,* Allan Tsung,1,* Takahashi Kaizu,1 Geetha Jeyabalan,1 Atsushi Ikeda,1 Lifang Shao,1 Guoyao Wu,2 Noriko Murase,1 and David A. Geller1

1Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania; and 2Department of Animal Science, Texas A&M University, College Station, Texas

Submitted 27 May 2006 ; accepted in final form 20 September 2006

Liver ischemia-reperfusion (I/R) injury is associated with profound arginine depletion due to arginase release from injured hepatocytes. The purpose of this study was to determine whether arginase inhibition with N{omega}-hydroxy-nor-L-arginine (nor-NOHA) would increase circulating arginine levels and decrease hepatic damage during liver I/R injury. The effects of nor-NOHA were initially tested in normal animals to determine in vivo toxicity. In the second series of experiments, orthotopic syngeneic liver transplantation (OLT) was performed after 18 h of cold ischemia time in Lewis rats. Animals were given nor-NOHA (100 mg/kg) or saline before and after graft reperfusion. In normal animals treated with nor-NOHA, there were no histopathological changes to organs, liver enzymes, serum creatinine, or body weight. In the OLT model, animals treated with saline exhibited markedly elevated serum transaminases and circulating arginase protein levels. Nor-NOHA administration blunted the increase in serum arginase activity by 80% and preserved serum arginine levels at 3 h after OLT. Nor-NOHA treatment reduced post-OLT serum liver enzyme release by 50%. Liver histology (degree of necrosis) in nor-NOHA-treated animals was markedly improved compared with the saline-treated group. Furthermore, use of the arginase inhibitor nor-NOHA did not influence polyamine synthesis owing to the decrease in ornithine levels. Arginase blockade represents a potentially novel strategy to combat hepatic I/R injury associated with liver transplantation.

liver transplantation; arginine; nitric oxide; preservation injury



Address for reprint requests and other correspondence: D. A. Geller, Starzl Transplantation Institute, 3459 Fifth Ave., Univ. of Pittsburgh, Pittsburgh, PA 15213 (e-mail: gellerda{at}upmc.edu)







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2007 by the American Physiological Society.